Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 941-944

  Udaondo, Patricia ^a,b   Garcia Delpech, Salvador ^a,c   Salom, David ^a,c   Garcia Pous, Maria ^a,c   Diaz Llopis, Manuel ^a,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

BCVA; BRVO; Macugen ; Pegaptanib sodium

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; VISUAL ACUITY;

EID: 79960428405     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s18873     Document Type: Article

References (12)

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282.
2. Battaglia M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1999; 237:1024-1027.
3. Roth DB, Cukras C, Radhakrishnan R, et al. Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging. 2008;39:446-454.
4. Patel PJ, Zaheer I, Karia N. Intravitral triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye. 2008;22: 60-64.
5. Haller JA, Bandello F, Belfort R Jr, et al; for the Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146.
6. Buchlolz PM, Buchlolz AP, Augustin AJ. Antivascular endothelial growth factor as an approach for macular edema. Dev Ophthalmol. 2010; 46:111-122.
7. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
8. Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol. 2010;94:1052-1056.
9. Campochiaro PA, Heier JS, Feiner L, et al; for the BRAVO investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology. 2010;117:1102-1112.
10. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419-425.
11. Wroblewski JJ, Wells JA 3rd, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch vein oclussion. Am J Ophthalmol 2010;149(1):147-154.
12. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53-67.